earnings
confidence high
sentiment neutral
materiality 0.50
TherapeuticsMD Q2 net loss narrows to $1.05M; evaluating strategic alternatives
TherapeuticsMD, Inc.
2024-Q2 EPS reported
-$0.16
revenue$547,000
- Net loss from continuing operations $1.05M ($0.09/sh) vs $2.4M ($0.24/sh) in Q2 2023.
- License revenue from Mayne License Agreement fell 46.5% to $234K from $437K.
- Operating expenses decreased 8.1% to $2.7M; cash and equivalents $5.2M as of June 30.
- Company continues to evaluate strategic alternatives including M&A or asset sale; no assurance of outcome.